IMIC(000516)2025-01-22 08:40Financial Projections - The estimated net profit for 2024 is projected to be a loss between 280 million and 215 million CNY, compared to a loss of 368.36 million CNY in the previous year[2] - The expected revenue for 2024 is between 4.79 billion and 4.85 billion CNY, an increase from 4.62 billion CNY in the previous year[2] - The basic earnings per share for 2024 is projected to be a loss between 0.12 CNY and 0.10 CNY per share, compared to a loss of 0.16 CNY per share in the previous year[2] - The net profit after deducting non-recurring gains and losses is expected to be a loss between 300 million and 245 million CNY, compared to a loss of 499 million CNY in the previous year[2] Business Performance - The company’s overall medical business has maintained stable development, with continuous enhancement of discipline strength and steady growth in revenue[5] - The revenue scale has not yet covered operational costs and period expenses, leading to the projected losses[5] Financial Data Integrity - The financial data provided is based on preliminary estimates by the company's finance department and has not been audited[6]